Monoclonal antibody which targets the critical ser186 residue for MDM2 function.
| Inventor | Institute |
|---|---|
| David Meek | University of Dundee |
| Cat. #: | 151309 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Genetics |
| Application: | WB ; IP ; WB |
| Target: | Murine Double Minute 2 protein (MDM2), Phosphorylated (Serine 186) |
| Reactivity: | Human |
| Clone: | 2G2 2.2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody which targets the critical ser186 residue for MDM2 function. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 90 kDa |
| Immunogen: | Peptide QRKRHKS(p)DSIS. S(p) represent a phosphorylated serine. This peptide represents the portion of MDM2 around Serine 186 |
| Immunogen Uniprot ID: | Q00987 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | MDM2 is a ubiquitin ligase whose principal function is the ubiquitination and degradation of p53 tumour suppressor protein. This promotes progression through the cell cycle and cell survival. MDM2 has been shown to negatively regulate p53 function. MDM2 binds and inhibits transactivation role played by p53 and overexpression of MDM2 can result in the inactivation of p53 and decrease its tumour suppressor function. MDM2 is over-expressed in many tumours, including soft tissue carcinomas and breast cancer. The phosphorylation of serines 166 and 186 is necessary for MDM2's translocation into the nucleus, thereby facilitating interaction with p53. More than 40 different alternatively spliced transcript variants of MDM2 have been isolated from both tumour and normal tissues. This antibody is directed against serine 186, which is crucial for MDM2 function. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Zhang et al. 2019. J Cell Physiol. 234(7):11330-11347. PMID: 30478915. Wei et al. 2013. Oncogene. 32(9):1110-20. PMID: 22525275. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.